Ljungberg B, Larsson P, Roos G, Stenling R, Wilson G
Department of Urology, University of Umeå, Sweden.
J Urol. 1994 Jun;151(6):1509-13. doi: 10.1016/s0022-5347(17)35288-6.
In 29 patients with renal cell carcinoma tumor cell kinetics were studied by in vivo labeling with 100 mg. iododeoxyuridine given 3 to 7 hours before nephrectomy. Two to 6 samples were analyzed from each tumor after fixation in ethanol. Iododeoxyuridine was analyzed by specific antibodies using flow cytometric analysis of labeled cells and parameters, such as labeling index and potential tumor doubling time, could be determined. Samples from 28 tumors were evaluable. Mean labeling index of the tumors was 2.7%, which was significantly different from the 0.35% index in kidney cortex tissue. There was no statistical difference in labeling index among the clinical stages. The mean potential tumor doubling time in the tumor cells was 20.3 days, which was significantly different compared with 137.7 days in kidney cortex tissue. There was a frequent intra-tumoral heterogeneity of potential tumor doubling times. Diploid and aneuploid samples had significantly different potential tumor doubling (mean 37.4 and 12.5 days, respectively). Potential tumor doubling had a significant impact on the survival time (p = 0.004), which also was noted in the patients with aneuploid tumors (p = 0.003). Our study shows that in vivo incorporation of iododeoxyuridine successfully can be analyzed in renal cell carcinoma. Potential tumor doubling time gives valuable prognostic information on the clinical behavior of the patients.
对29例肾细胞癌患者，在肾切除术前3至7小时给予100毫克碘脱氧尿苷进行体内标记，研究肿瘤细胞动力学。乙醇固定后，从每个肿瘤中分析2至6个样本。通过使用标记细胞的流式细胞术分析特异性抗体来分析碘脱氧尿苷，并确定标记指数和潜在肿瘤倍增时间等参数。来自28个肿瘤的样本可进行评估。肿瘤的平均标记指数为2.7%，与肾皮质组织中的0.35%指数有显著差异。各临床分期的标记指数无统计学差异。肿瘤细胞的平均潜在肿瘤倍增时间为20.3天，与肾皮质组织中的137.7天相比有显著差异。潜在肿瘤倍增时间在肿瘤内经常存在异质性。二倍体和非整倍体样本的潜在肿瘤倍增时间有显著差异（分别为平均37.4天和12.5天）。潜在肿瘤倍增时间对生存时间有显著影响（p = 0.004），在非整倍体肿瘤患者中也有此现象（p = 0.003）。我们的研究表明，在肾细胞癌中可以成功分析碘脱氧尿苷的体内掺入情况。潜在肿瘤倍增时间为患者的临床行为提供了有价值的预后信息。
